Association of TNF-α rs1800629 with Adult Acute B-Cell Lymphoblastic Leukemia.
TNF–α
acute lymphoblastic leukemia
polymorphism
rs1800629
Journal
Genes
ISSN: 2073-4425
Titre abrégé: Genes (Basel)
Pays: Switzerland
ID NLM: 101551097
Informations de publication
Date de publication:
13 07 2022
13 07 2022
Historique:
received:
21
06
2022
revised:
05
07
2022
accepted:
06
07
2022
entrez:
27
7
2022
pubmed:
28
7
2022
medline:
29
7
2022
Statut:
epublish
Résumé
TNF−α influences lymphomagenesis by upregulating proinflammatory and antiapoptotic pathways. In this study, we evaluated the frequency of TNF−α rs1800629 (−308 G>A) polymorphism in newly diagnosed adult patients with acute lymphoblastic leukemia (ALL) and its correlation with age at diagnosis, gender and subtype of ALL. In this case control study, a total of 330 individuals were recruited, including 165 newly diagnosed adult patients with ALL, from the Radiation and Isotope Center in Khartoum (RICK) and 165 healthy normal controls. TNF−α rs1800629 polymorphism was tested through allele-specific polymerase chain reaction (PCR) assay. The frequency of the rs1800629 GA genotype was high (70.9% vs. 60%, OR = 1.84) in the patient group as compared to healthy controls, whereas GG and AA genotypes did not exhibit any statistically significant difference between controls and patients. Based on subtype, GG and GA rs1800629 genotypes showed increased risk of B-ALL (OR 0.46 and 2.12, respectively), whereas rs1800629 GG, GA and AA genotypes did not show any disease association with T-ALL (p > 0.05). Age at diagnosis and gender did not exhibit any association of rs1800629 with ALL in the patient group. In conclusion, rs1800629 is associated with high risk of adult B-ALL, with an insignificant effect of age at diagnosis and gender.
Identifiants
pubmed: 35886021
pii: genes13071237
doi: 10.3390/genes13071237
pmc: PMC9320751
pii:
doi:
Substances chimiques
TNF protein, human
0
Tumor Necrosis Factor-alpha
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Références
Immunol Rev. 2011 Nov;244(1):115-33
pubmed: 22017435
Int J Immunogenet. 2006 Feb;33(1):21-4
pubmed: 16426238
Leuk Lymphoma. 2008 Nov;49(11):2163-9
pubmed: 19021060
Br J Haematol. 1997 Apr;97(1):107-12
pubmed: 9136948
Carcinogenesis. 2007 Mar;28(3):704-12
pubmed: 17056605
In Vivo. 2016 May-Jun;30(3):265-9
pubmed: 27107085
Int J Cancer. 2007 Aug 15;121(4):819-24
pubmed: 17390373
Am J Epidemiol. 2015 Apr 15;181(8):549-62
pubmed: 25731888
Cancer Lett. 2005 Jun 1;223(1):113-9
pubmed: 15890243
Mayo Clin Proc. 2016 Nov;91(11):1645-1666
pubmed: 27814839
BMC Infect Dis. 2020 Mar 14;20(1):221
pubmed: 32171247
Tumour Biol. 2014 Dec;35(12):12509-17
pubmed: 25204673
PLoS One. 2009;4(4):e5360
pubmed: 19390683
Front Immunol. 2018 Apr 19;9:784
pubmed: 29725328
Br J Haematol. 2002 Dec;119(4):985-7
pubmed: 12472577
Leuk Res. 2012 Jun;36(6):694-8
pubmed: 22177457
Microsc Res Tech. 2000 Aug 1;50(3):216-28
pubmed: 10891887
Cold Spring Harb Perspect Biol. 2014 Dec 18;7(4):a016279
pubmed: 25524549
Semin Immunol. 2014 Jun;26(3):191-202
pubmed: 24996229
Biochim Biophys Acta. 2009 Mar;1792(3):163-72
pubmed: 19708125
Ai Zheng. 2003 Aug;22(8):861-6
pubmed: 12917036
Iran J Basic Med Sci. 2013 Sep;16(9):990-5
pubmed: 24171078
Am J Epidemiol. 2010 Apr 1;171(7):749-64
pubmed: 20228139
Lancet. 2020 Apr 4;395(10230):1146-1162
pubmed: 32247396
Tumori. 2017 Jan 21;103(1):53-59
pubmed: 27647233